News
-
-
-
COMMUNIQUÉ DE PRESSE
MindBio Therapeutics Scientists Present Landmark Women’s Health Trials. Company To Release Phase 2A Depression Trial Secondary Data This Month
MindBio Therapeutics Corp. presents groundbreaking women's health trials for microdosing treatments, showcasing Dr. Rachael Sumner and upcoming data release on Phase 2A trial results. Chief Executive Justin Hanka discusses future growth plans -
COMMUNIQUÉ DE PRESSE
MindBio Therapeutics Scientists Present Landmark Women’s Health Trials. Company To Release Phase 2A Depression Trial Secondary Data This Month
MindBio Therapeutics Corp. showcases women's health trials and upcoming data presentation on Phase 2A trial of MB22001 for Major Depressive Disorder. Company pioneering microdosing LSD for mental health conditions -
-
-
COMMUNIQUÉ DE PRESSE
MindBio Is Exploring Dual Listing on A Senior Exchange with Multiple Phase 2B Clinical Trials Underway Supported by Positive Trial Data and Planning for Phase 3
MindBio announces successful completion of Phase 1 and Phase 2a Clinical Trials for MB22001 in treating Major Depressive Disorder. Company plans dual listing on senior exchange -
-
-
COMMUNIQUÉ DE PRESSE
MindBio Therapeutics Announces Landmark Women’s Health CNS Drug Trials
MindBio Therapeutics Corp. has received regulatory approval for clinical trials using MB22001 to address PMS and PMDD in menstruating individuals. The trials aim to assess the drug's mood-related effects during different menstrual phases
